LTB4R and pancreatic neoplasm: A few clinical trials have been conducted using LY293111, a well-tolerated inhibitor of BLT1, in patients with pancreatic cancer and non-small cell lung cancer; no significant difference in short-term survival was noted from these human studies (Ding et al., 2005; Janne et al., 2014).